Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.

You may also be interested in...



Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles

Firm halts manufacturing and distribution of nearly all products.

Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles

Firm halts manufacturing and distribution of nearly all products.

Vivus Gets FDA Approval For Evamist Estradiol Spray

Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.

Related Content

Topics

UsernamePublicRestriction

Register

PS066765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel